Shinya Otsuka

Dr. Shinya Otsuka

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2010 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
FBFumiya Baba
Fumiya Baba
YSYuta Shibamoto
Yuta Shibamoto
HOHiroyuki Ogino
Hiroyuki Ogino
RMRumi Murata
Rumi Murata
CSChikao Sugie
Chikao Sugie
AMAkifumi Miyakawa
Akifumi Miyakawa
The treatment schedules for stereotactic body radiotherapy (SBRT) for lung cancer vary from institution to institution. Several reports have indicated that stage IB patients had worse outcomes than stage IA patients when the same dose was used. We evaluated the clinical outcomes of SBRT for stage I non-small cell lung cancer (NSCLC) treated with different doses depending on tumor diameter.

1 December 2011 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SOShinya Otsuka
Shinya Otsuka
YSYuta Shibamoto
Yuta Shibamoto
HIHiromitsu Iwata
Hiromitsu Iwata
RMRumi Murata
Rumi Murata
CSChikao Sugie
Chikao Sugie
HOHiroyuki Ogino
Hiroyuki Ogino

1 August 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
TMTaro Murai
Taro Murai
YSYuta Shibamoto
Yuta Shibamoto
TNTakeshi Nishiyama
Takeshi Nishiyama
FBFumiya Baba
Fumiya Baba
AMAkifumi Miyakawa
Akifumi Miyakawa
HIHiromitsu Iwata
Hiromitsu Iwata
Organizing pneumonia (OP), so called bronchiolitis obliterans organizing pneumonia after postoperative irradiation for breast cancer has been often reported. There is little information about OP after other radiation modalities. This cohort study investigated the clinical features and risk factors of OP after stereotactic ablative radiotherapy of the lung (SABR).

7 January 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
KTKotoha Tatekawa
Kotoha Tatekawa
HIHiromitsu Iwata
Hiromitsu Iwata
TKTakatsune Kawaguchi
Takatsune Kawaguchi
SISatoshi Ishikura
Satoshi Ishikura
FBFumiya Baba
Fumiya Baba
YSYuta Shibamoto
Yuta Shibamoto
The overall treatment time of stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer is usually 3 to over 10 days. If it is longer than 7 days, tumor volume expansion during SBRT may jeopardize the target dose coverage. In this study, volume change of stage I NSCLC during SBRT was investigated.

6 November 2019 in Journal of Radiation Research
Verified
Journal Article
Open access
PDF file
TMTaro Murai
Taro Murai
MMMasayuki Matsuo
Masayuki Matsuo
HTHidekazu Tanaka
Hidekazu Tanaka
YMYoshihiko Manabe
Yoshihiko Manabe
TTTaiki Takaoka
Taiki Takaoka
YSYuta Shibamoto
Yuta Shibamoto
The purpose of this multi-institutional Phase II trial study was to prospectively investigate the efficacy of the herbal medicine TJ-14 for acute radiation-induced enteritis (ARE). TJ-14 was administered orally as a first-line treatment for ARE. The primary end point was efficacy at 1 week. The secondary end points were: (i) the efficacy of TJ-14 at 2 and 3 weeks after its administration, (ii) the quality of life score (FACT-G) at 1, 2 and 3 weeks after its administration, and (iii) adverse events. If the efficacy of TJ-14 was observed in eight patients or fewer, its efficacy was rejected. Results: Forty patients receiving pelvic radiotherapy were enrolled. Of these, 22 developed ARE and received TJ-14. Among these, 19 had cervical cancer and 9 received chemoradiotherapy. TJ-14 efficacy was shown in 19 out of the 22 patients (86%). Stool frequency per day at 1 week significantly decreased (mean ± SD: 4.9 ± 2.1 vs 3.7 ± 1.9, P = 0.02). This effect continued at 2 (2.2 ± 1.4, P = 0.004) and 3 weeks (2.1 ± 0.9, P = 0.05). Thirteen out of the 22 patients (59%) continued TJ-14 until the end of radiotherapy. FACT-G score deterioration was not observed after the administration of TJ-14. Grade 1 hypokalemia was observed in 4 patients, and Grade 1 constipation in 3. We concluded that TJ-14 is sufficiently promising to be examined in a Phase III trial. A randomized controlled trial is currently being planned.

29 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MNMasanari Niwa
Masanari Niwa
Natsuo TomitaNatsuo Tomita
Natsuo Tomita
HIHiromichi Ishiyama
Hiromichi Ishiyama
HKHijiri Kaneko
Hijiri Kaneko
YOYukihiko Oshima
Yukihiko Oshima
AHAkio Hiwatashi
Akio Hiwatashi
Background: Extramammary Paget’s disease (EMPD) is a rare cutaneous carcinoma that typically affects the elderly and is frequently observed in genital and perianal regions. We analyzed the outcomes and prognostic factors for EMPD after radiation therapy (RT). Methods: We analyzed data from 81 patients with non-metastatic EMPD who received either RT alone or in combination with surgery and/or chemotherapy. The median radiation dose was 56 Gy in 28 fractions. Local control (LC), progression-free survival (PFS), and overall survival (OS) rates were calculated using the Kaplan–Meier method. Multivariate analyses were performed using the Cox proportional hazards model. Late adverse events were evaluated by NCI-CTCAE version 5.0. Results: The median age was 78 years, and the median follow-up period was 36 months. The three-year LC, PFS, and OS rates were 75%, 52%, and 80%, respectively. Multivariate analyses identified the presence of lymph node (LN) metastasis, the absence of surgery, and the omission of elective nodal irradiation (i.e., local irradiation only) as significant factors for unfavorable LC (p = 0.01, 0.02, and 0.006) and PFS (p = 0.001, 0.04, and 0.03). LN metastasis was also a significant factor for unfavorable OS (p = 0.005). One patient developed grade 2 skin infection, and another developed grade 3 lymphedema; no grade 4 or higher toxicity was observed. Conclusions: The present results revealed prognostic factors for EMPD after RT and suggest that the absence of surgery and omission of elective nodal irradiation worsened outcomes. A prospective study is needed to establish an optimal treatment strategy for this rare malignancy, which is common in the elderly.